Gm2 Gangliosidoses Stocks List
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 0.53 | |
IBBQ | B | Invesco Nasdaq Biotechnology ETF | 0.04 | |
IBB | B | iShares Nasdaq Biotechnology Index Fund | 0.03 | |
BIB | C | ProShares Ultra Nasdaq Biotechnology | 0.03 | |
IWM | C | iShares Russell 2000 ETF | 0.01 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Jul 1 | TSHA | Insider Buyers At Taysha Gene Therapies Sitting On US$24m Profit |
Related Industries:
Biotechnology
- Gm2 Gangliosidoses
Gm2 Gangliosidoses is a group of rare, inherited disorders caused by the buildup of a fatty substance called GM2 ganglioside in the body's cells. This buildup can cause a wide range of symptoms, including intellectual disability, seizures, movement problems, and vision and hearing loss. Treatment is supportive and may include physical, occupational, and speech therapy, as well as medications to control seizures.
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles